Comparing the current results to its competitors, Reshape Lifesciences Inc reported Revenue decrease in the 1 quarter 2026 year on year by -97.16 %, despite the revenue increase by the most of its competitors of 8.18 %, recorded in the same quarter.
Reshape Lifesciences Inc, slower than the average decrease reported by the company's competitors of -39.13 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -39.13 %
Reshape Lifesciences Inc's Comment on Competition and Industry Peers
The company faces potential competition from several firms developing treatments for wounds, uveitis, inflammatory acne, and other immune-inflammatory conditions using various technologies. Named competitors include Tarsier Pharma, Eli Lilly, Eyepoint Pharmaceuticals, Bausch Health, Sun Pharma, and Almirall. These companies may possess greater financial resources and expertise in research and development, manufacturing, preclinical testing, clinical trials, and approved products. Additionally, mergers and acquisitions within the pharmaceutical and biotechnology sectors may influence the competitive landscape by consolidating resources among fewer competitors.
July 9, 2024
In an exciting development within the pharmaceutical industry, ReShape Lifesciences has announced the signing of a definitive merger agreement with Vyome Therapeutics, a clinical stage specialty pharmaceutical company focused on tackling immuno-inflammatory diseases with unmet medical need. This significant merger aims to bring forth groundbreaking treatment options for patients worldwide and reshape the landscape of this demanding healthcare sector.ReShape Lifesciences is a prominent player in the medical device sector, specializing in developing innovative solutions to address the global obesity epidemic. By combining forces with Vyome Therapeutics, which concentrates on addressing immuno-inflammatory ailm...
Allurion Technologies Inc is a medical device company that specializes in developing non-surgical solutions for weight loss. Their business model is centered around providing a comprehensive weight loss program that combines their innovative medical device, the Elipse Balloon, with personalized coaching and support. They target individuals seeking a non-invasive and convenient approach to achieving their weight loss goals.
Iridex Corp's business model revolves around providing advanced medical devices and solutions for the treatment of eye conditions, primarily focused on ophthalmology.
Intuitive Surgical Incs business model focuses on delivering robotic surgical systems, particularly the da Vinci Surgical System, which facilitates minimally invasive surgeries. Revenue is generated through system sales, instruments, accessories, and services, including training and maintenance for healthcare providers.
Johnson & Johnson operates as a multinational healthcare company with a diversified business model that spans pharmaceuticals, medical devices, and consumer health products. By focusing on innovation and strategic acquisitions, the company aims to improve global health and well-being.
Lensar Inc is a medical technology company that operates through a business model focused on the development and commercialization of advanced laser systems for ophthalmic procedures. They aim to provide innovative solutions to healthcare professionals in order to enhance precision, safety, and efficiency in eye surgeries.
Sources:
Reshape Lifesciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Reshape Lifesciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
